EA201100078A1 - DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS - Google Patents

DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS

Info

Publication number
EA201100078A1
EA201100078A1 EA201100078A EA201100078A EA201100078A1 EA 201100078 A1 EA201100078 A1 EA 201100078A1 EA 201100078 A EA201100078 A EA 201100078A EA 201100078 A EA201100078 A EA 201100078A EA 201100078 A1 EA201100078 A1 EA 201100078A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
pyrimidine
kinase inhibitors
pyrimidine derivatives
igf
Prior art date
Application number
EA201100078A
Other languages
Russian (ru)
Inventor
Томас Х Марсилье, III
Вэньшу Лу
Бэй Чэнь
Сяосюй Хэ
Сончунь Цзян
Куньйон Ян
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201100078A1 publication Critical patent/EA201100078A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны новые производные пиримидина и содержащие их фармацевтические композиции и способы применения таких соединений. Например, производные пиримидина, предлагаемые в настоящем изобретении, можно применять для лечения, облегчения протекания или предупреждения патологического состояния, которое реагирует на ингибирование инсулиноподобного фактора роста (IGF-1R) или киназы анапластической лимфомы (ALK).The application describes new pyrimidine derivatives and pharmaceutical compositions containing them and methods of using such compounds. For example, the pyrimidine derivatives of the present invention can be used to treat, alleviate, or prevent a pathological condition that responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK).

EA201100078A 2008-06-25 2009-06-24 DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS EA201100078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
PCT/US2009/048509 WO2009158431A2 (en) 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201100078A1 true EA201100078A1 (en) 2011-08-30

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100078A EA201100078A1 (en) 2008-06-25 2009-06-24 DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS

Country Status (11)

Country Link
EP (1) EP2331526A2 (en)
JP (1) JP2011526291A (en)
KR (1) KR20110020940A (en)
CN (1) CN102203083A (en)
AU (1) AU2009262198B2 (en)
BR (1) BRPI0914545A2 (en)
CA (1) CA2729546A1 (en)
EA (1) EA201100078A1 (en)
MX (1) MX2010014568A (en)
UA (1) UA101057C2 (en)
WO (1) WO2009158431A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
JP2013522215A (en) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー Combined anticancer therapy
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
BR112014011219B1 (en) * 2011-11-29 2022-08-23 Genentech, Inc. AMINOPYRIMIDINE DERIVATIVES, THEIR USES, AND PHARMACEUTICAL COMPOSITION
RU2675850C2 (en) 2012-11-06 2018-12-25 Шанхай Фокон Фармасьютикал Ко Лтд Alk kinase inhibitors
CA2905993C (en) * 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
US10023593B2 (en) * 2014-05-30 2018-07-17 Beijing Pearl Biotechnology Limited Liability Company ALK kinase inhibitor, and preparation method and uses thereof
EP3523289A1 (en) * 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
CN107488148A (en) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 A kind of hydrocinnamamide insecticides and preparation method thereof
BR112020012635A2 (en) 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202045008A (en) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-substituted isoxazole/isoxazoline (hetero) arylamidine compounds, preparation and use thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
EP1656372B1 (en) * 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
DK1663242T3 (en) * 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds and use as antiproliferative agents
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
JP5208516B2 (en) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド Pyrimidine derivatives as kinase modulators and methods of use
JP2008540436A (en) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド JAK kinase inhibitors and uses thereof
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
BRPI0722383A2 (en) * 2006-12-08 2012-06-05 Irm Llc protein kinase inhibiting compounds, compositions containing them as well as their uses
EA017405B9 (en) * 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Compounds and compositions as protein kinase inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
MX2010008700A (en) * 2008-02-22 2010-08-30 Hoffmann La Roche Modulators for amyloid beta.

Also Published As

Publication number Publication date
CN102203083A (en) 2011-09-28
CA2729546A1 (en) 2009-12-30
WO2009158431A3 (en) 2010-03-11
BRPI0914545A2 (en) 2017-05-23
KR20110020940A (en) 2011-03-03
AU2009262198A1 (en) 2009-12-30
MX2010014568A (en) 2011-03-29
JP2011526291A (en) 2011-10-06
AU2009262198B2 (en) 2012-09-27
EP2331526A2 (en) 2011-06-15
UA101057C2 (en) 2013-02-25
WO2009158431A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
EA201100077A1 (en) DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS
EA201100078A1 (en) DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS
MX2010002336A (en) Compounds and compositions as kinase inhibitors.
EA201001597A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA200970557A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA201101341A1 (en) KINASE INHIBITIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITION BASED ON THEIR BASIS
EA201001596A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA201100688A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
MX2012013197A (en) Indazole inhibitors of kinase.
MX2012000711A (en) Pyrrolopyrazine inhibitors of kinases.
MX2015011514A (en) Heteroaryl compounds and uses thereof.
EA201100580A1 (en) IMIDAZOPIRIDAZINCARBONITRILE USED AS KINASE INHIBITORS
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA200970156A1 (en) PYRDISINOUS DERIVATIVES
MX2012000709A (en) Pyrrolopyridine inhibitors of kinases.
MY181020A (en) Heteroaryl compounds and uses thereof
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX2011012369A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors.
EA201491647A1 (en) BASED ON ARILETHER KINAZ INHIBITORS
EA201071224A1 (en) LIMK2 INHIBITORS, COMPOSITIONS CONTAINING THEM, AND METHODS OF THEIR USE
EA201590268A1 (en) ARYLACTAM KINASE INHIBITORS
MX2009012079A (en) Condensed heterocyclic compounds as inhibitors of protein kinases.
MX2009003793A (en) Kinase inhibitors.
TN2010000602A1 (en) Pyrimidine derivatives as kinase inhibitors
CU20100259A7 (en) PIRIMIDINE DERIVATIVES AS QUINASA INHIBITORS